Menlo Park, Calif., October 12, 2023 — HALO Precision Diagnostics™ (“HALO”), a leader
in early disease detection using precision diagnostics, today announced the appointment of
Thomas P. Slavin, M.D., as chief scientific officer.
Slavin is triple-board-certified in clinical genetics, molecular diagnostics, and pediatrics. He will
lead scientific operations and innovation at HALO, supporting the continued evolution of the
company’s robust imaging and precision diagnostic offerings across its growing network of
owned and partner precision diagnostic centers.
“Dr. Slavin is a highly respected clinical leader and scientist in genetic testing,” said Michael
Uhl, HALO chief executive officer. “We are fortunate to welcome him to HALO as we further
our mission to save lives with early disease detection.”
HALO’s molecular diagnostics approach, in combination with its proprietary precision
diagnostics platform, integrates advanced imaging to deliver comprehensive clinical insights for
early disease detection and treatment. HALO currently has clinically validated care pathways for
prostate cancer, breast cancer, and cardiovascular disease, as well as programs in development
for neurodegenerative and other life-threatening diseases.
“I have dedicated my career to bringing genetic solutions to patients through education, research,
and advocacy,” said Slavin. “HALO’s integrated approach to early disease detection is incredibly
unique and I look forward to contributing to the company’s life-saving work.”
Most recently, Slavin served as chief medical officer at Myriad Genetics. He is an expert in
hereditary cancer genetics and cancer screening and prevention, with extensive expertise in
oncology product commercialization and evaluating molecular diagnostic technologies.
Slavin is a renowned speaker and researcher in the field of medical genetics, publishing more
than 80 journal articles collectively evaluating genomic data from more than 500,000 patients.
Last month, HALO also announced the appointment of John Craighead, Ph.D., as chief operating
officer and chief financial officer.
